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Rationale: Systemic glucocorticoids are used therapeutically to treat
a variety of medical conditions. Epigenetic processes such as DNA
methylation may reflect exposure to glucocorticoids and may be
involved in mediating the responses and side effects associated
with these medications.
Objectives: To test the hypothesis that differences in DNA methyla-
tion are associated with current systemic steroid use.
Methods: We obtained DNAmethylation data at 27,578 CpG sites in
14,475 genes throughout the genome in two large, independent
cohorts: the International COPD Genetics Network (ndiscovery ¼
1,085) and the Boston Early Onset COPD study (nreplication ¼ 369).
Sites were tested for association with current systemic steroid use
using generalized linear mixed models.
Measurements and Main Results: A total of 511 sites demonstrated
significant differential methylation by systemic corticosteroid use
in all three of our primary models. Pyrosequencing validation con-
firmed robust differential methylation at CpG sites annotated to
genes such as SLC22A18, LRP3, HIPK3, SCNN1A, FXYD1, IRF7, AZU1,
SIT1, GPR97, ABHD16B, and RABGEF1. Functional annotation cluster-
ing demonstrated significant enrichment in intrinsic membrane
components, hemostasis and coagulation, cellular ion homeostasis,
leukocyte and lymphocyte activation and chemotaxis, protein trans-
port, and responses to nutrients.
Conclusions: Our analyses suggest that systemic steroid use is associ-
ated with site-specific differential methylation throughout the ge-
nome. Differentially methylated CpG sites were found in biologically
plausible and previously unsuspected pathways; these genes and
pathways may be relevant in the development of novel targeted
therapies.
Keywords: DNA methylation; glucocorticoids; chronic obstructive pul-
monary disease
Systemic glucocorticoids possess potent antiinflammatory, im-
munomodulatory, and antineoplastic properties and are integral
in the treatment of chronic obstructive pulmonary disease (COPD)
and asthma exacerbations, autoimmune diseases, allergic reac-
tions, and certain malignancies. However, despite their clinical
utility, systemic glucocorticoid use is often complicated by mul-
tiple side effects, including weight gain and redistribution of
body fat, osteoporosis, cardiovascular disease, impaired im-
mune response and wound healing, and alterations in glucose
and lipid metabolism. The responses and side effects experienced
by individuals exposed to glucocorticoids are highly variable and
may persist for extended periods after drug withdrawal; these phe-
nomena may be mediated through epigenetic processes.
Epigenetic changes, such as histone modifications (1, 2),
DNA methylation, and alterations in chromatin structure, vary
between individuals (3) and can affect glucocorticoid receptor
expression and binding (3, 4) as well as the subsequent re-
sponses to endogenous (5) or exogenously administered (1, 2,
6) steroids. Conversely, glucocorticoid exposure can cause epi-
genetic changes and may be mediated in part through changes
in the expression or activity of DNA methyltransferases (7–9).
Dynamic, site-specific changes in DNA methylation have been
observed after glucocorticoid exposure in vitro (4) and in vivo
(10). However, investigations into the associations between glu-
cocorticoids and DNA methylation remain limited to a small
number of CpG sites within selected candidate genes (10–13).
We hypothesized that, given the extensive systemic effects of
therapeutic glucocorticoids, exposure to these medications would
(Received in original form July 23, 2012; accepted in final form September 27, 2012)
Supported by National Institutes of Health grants R01HL089438, T32 HL007427,
and K12HL089990; by the Doris Duke Foundation Clinician Scientist Develop-
ment Award (D.L.D.); and by National Institute of Environmental Health Sciences-
Harvard School of Public Health New Investigator Fund grant ES00002 (A.B.).
Author Contributions: E.S.W. and W.Q. contributed to the concept and design,
statistical support, data analysis, and interpretation of the data. A.B. contributed
to the concept of the study and the interpretation of the data. V.J.C. contributed
to the statistical support and analysis of the data. H.B. participated in the design
and performance of the experiments. S.I.R., A.A., W.H.A., and D.A.L. contributed
to the concept of the study and to the acquisition of the data. D.L.D. contributed
to the funding, concept and design, data collection, statistical support, analysis,
and interpretation of the data. All authors contributed substantially to drafting
and editing the manuscript.
Correspondence and requests for reprints should be addressed to Emily S. Wan,
M.D., M.P.H., 181 Longwood Ave, 4th floor, Boston, MA 02115. E-mail:
reesw@channing.harvard.edu
This article has an online supplement, which is accessible from this issue’s table of
contents at www.atsjournals.org
Am J Respir Crit Care Med Vol 186, Iss. 12, pp 1248–1255, Dec 15, 2012
Copyright ª 2012 by the American Thoracic Society
Originally Published in Press as DOI: 10.1164/rccm.201207-1280OC on October 11, 2012
Internet address: www.atsjournals.org
AT A GLANCE COMMENTARY
Scientific Knowledge on the Subject
Systemic corticosteroids are associated with a wide range of
therapeutic responses and side effects that may persist after
drug withdrawal. These characteristics suggest a possible
role for epigenetic modifications. Previous epigenetic studies
on steroid exposure have examined histone modifications or
DNA methylation of candidate genes involved in steroid
biosynthesis, metabolism, or receptors.
What This Study Adds to the Field
Our study explores the association of differential DNA
methylation at sites throughout the entire genome. We
report robustly associated sites in biologically plausible and
previously unsuspected pathways.
be associated with differential methylation in peripheral blood
DNA at multiple sites throughout the genome. Some of these results
have been previously reported in the form of an abstract (14).
METHODS
Subjects and Cohorts
The discovery cohort consisted of 1,085 subjects participating in the In-
ternational COPD Genetics Network (15, 16) (ICGN), a family-based
study with probands between the ages of 45 and 65 years, 5 or more
pack-years of cigarette smoking, FEV1 less than 60% predicted, and
a FEV1/FVC ratio of less than 90% predicted. Siblings of probands
with at least 5 pack-years of cigarette smoking were also enrolled. The
replication cohort consisted of 369 subjects from the Boston Severe
Early-Onset COPD Study (17) (EOCOPD), a family-based study
where probands have an FEV1 less than 40% predicted by age 53 in
the absence of severe a-1 antitrypsin deficiency. Although extended
pedigrees were recruited, DNA methylation data were obtained only
on probands and their siblings. The protocols were approved by the
appropriate Internal Review Boards; all subjects provided written in-
formed consent.
Variable Definitions
Subjects in ICGN were asked to list all current medications. Current
systemic steroid use was present if they answered affirmatively to the
following questions: “Are any of the above listed medications steroid/
prednisone pills?” and “Currently taking?” Subjects in EOCOPD
were considered to have current systemic steroid use if they responded
affirmatively to the question “Do you take prednisone?” For both
cohorts, current smoking was defined as a positive response to the ques-
tion “Do you currently smoke cigarettes (as of 1 month ago)?” Obstruc-
tive lung disease was defined as an FEV1/FVC ratio of less than 0.7.
DNA Extraction, Bisulfite Treatment,
and Methylation Array
DNA was extracted from whole blood. Quantitative assessment of
methylation was performed on bisulfite-converted DNA using the Illu-
mina (San Diego, CA) Infinium HumanMethylation27K BeadChip.
Methylation at each site is expressed as the Illumina “b value” (b),
a variable that ranges from zero (no methylation) to 1 (complete meth-
ylation). CpG sites are discussed using the industry-assigned identifier
(“cg”) as outlined in the Illumina HumanMethylation27K manifest.
The protocol is outlined in the online supplement (18).
Pyrosequencing
Technical validation of selected sites was performed in the ICGN cohort
using the Pyromark96MD (Qiagen Inc., Valencia, CA). Details are pro-
vided in the online supplement.
Statistical Analysis
The ComBat (19) function as implemented in the sva package (20, 21)
in R (release 2.12) was used to account for batch effects. To account for
familial correlations in the data, generalized linear mixed models (22)
were used to analyze the methylation data. The Illumina “b” value was
modeled as the dependent variable, with oral steroid use included as
the independent variable. Models were adjusted for age, sex, and FEV1
% predicted (Model 1); pack-years of smoking (Model 2); and current
smoking status (Model 3). CpG sites with a P value below the
Bonferroni-adjusted threshold for significance (,1.89 3 1026) in
ICGN and a P value of less than 0.05 with the same direction of effect
in EOCOPD were considered significant.
Subgroup Analysis: Matched Cohort
Subjects in ICGN who reported current systemic steroid use were
matched (1:1) by sex, age (62 yr), and FEV1 % predicted (610%) with
subjects who did not report current systemic steroid use (ntotal ¼ 160).
Differences in the mean Illumina b values were tested using an unpaired
Student’s t test.
RESULTS
The characteristics of the subjects in each cohort are listed in
Table 1, and the ranges for continuous variables by current
systemic steroid use are shown in Table E1 in the online sup-
plement. Eighteen subjects were missing a response for oral
steroid use in the EOCOPD study and were excluded from
analysis. Approximately 7.4 and 14.2% of subjects reported
current systemic steroid use in the ICGN and EOCOPD
cohorts, respectively. By design, subjects in the EOCOPD co-
hort had a lower mean age; the higher prevalence of female
subjects in the EOCOPD cohort has also been previously de-
scribed (17, 23). Subjects who reported current systemic steroid
use had significantly lower FEV1 % predicted, lower rates of
current smoking, higher rates of inhaled corticosteroid use, and
greater pack-years of cumulative smoke exposure than subjects
who were not on steroids in both cohorts. Although the majority
of subjects reporting current systemic steroid use had obstruc-
tive lung disease, four subjects in ICGN and two subjects in
EOCOPD reporting systemic steroid use did not have obstruc-
tion as measured by spirometry.
In Model 1, 614 sites demonstrated significant differential
methylation with respect to systemic steroid use; the top 20 sites
by Liptak-combined P values (24, 25) are illustrated in Table 2,
and the complete list of significant sites is reported in Table E2.
In Model 2, 599 CpG sites were significantly associated with
current steroid use (Table E3). In Model 3, 514 sites were sig-
nificantly associated with current systemic steroid use (Table
E4). A total of 511 sites were significant in Models 1, 2, and 3;
TABLE 1. COHORT CHARACTERISTICS
Current Systemic Steroid Use
ICGN EOCOPD*
Yes (n ¼ 80) No (n ¼ 1,005) Yes (n ¼ 50) No (n ¼ 301)
Age 57.7 (6.7) 57.2 (8.2) 49.0 (3.9)† 47.2 (7.6)
Male gender 43 (53.8%) 547 (54.4%) 11 (22.0%)† 114 (37.9%)
Current smokers 23 (28.8%) 373 (37.1%) 5 (10.0%)† 90 (29.9%)
Pack-years 48.7 (26.7)† 41.1 (26.1) 37.6 (19.3)† 27.2 (23.1)
Inhaled steroid use 58 (72.5%)† 324 (32.2%) 39 (78%)† 85 (28.2%)
FEV1% predicted 36.3 (18.6)
† 71.4 (33.1) 18.5 (10.0)†,‡ 62.3 (33.7)‡
Definition of abbreviations: EOCOPD ¼ Early Onset COPD Study; ICGN ¼ International COPD Genetics Network.
Data are presented as n (%) or mean (SD).
* Eighteen subjects in EOCOPD cohort were missing response to systemic and inhaled steroid data and were excluded
from analysis.
yUnivariate P value , 0.05 when compared with subjects who are not currently taking systemic steroids.
z Prebronchodilator values.
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these are listed in Table E5. To explore the possibility of over-
adjustment due to incorporating age and sex as covariates simul-
taneously with FEV1 % predicted values, we repeated the above
analyses substituting unadjusted FEV1 (in liters) for FEV1 %
predicted. As expected, the number of significant sites was in-
creased in the unadjusted FEV1 analysis (data not shown). The
overlap between the results obtained using unadjusted FEV1 and
FEV1 % predicted was excellent, with nearly identical ranking of
the most highly associated sites.
Functional annotation clustering performed using the official
HUGO gene symbol annotated to each of the 511 overlapping
sites with a high classification stringency in the database for An-
notation, Visualization, and Integrated Discovery Bioinfor-
matics Resources 6.7 (26, 27) showed significant enrichment in
genes annotated to the following processes: intrinsic membrane
components, hemostasis and coagulation, cellular ion homeo-
stasis, leukocyte and lymphocyte activation and chemotaxis,
protein transport, and responses to nutrients (Table 3).
Pyrosequencing validation was performed for selected highly
associatedCpG sites chosen on the basis of a preliminary analysis
in the ICGN cohort. Robust differences in mean methylation by
current systemic steroid use were confirmed for all sites exam-
ined (Table 4) and are illustrated in Figure E1.
A recent publication by Du and colleagues (28) raised the
issue of heteroscedasticity at CpG sites with extremely low
(,0.2) or high (.0.8) Illumina b values and suggested the use
of M values (defined as the log2 of Cy5/Cy3 ratios) in lieu of b
values for association testing. We repeated our analyses using
the same covariates and criteria for significance as our b-value
analyses and obtained similar overall results. In Model 1, 724
sites were significant in the M-value analysis, 585 of which over-
lapped with the 614 sites reported in the b-value analysis. For
Model 2, 707 sites were significant in the M-value analysis, 567
of which overlapped with the 599 sites reported in the b-value
analysis. In Model 3, 616 CpG sites were significant in the
M-value analysis, 483 of which overlapped with the 514 sites
reported in the b-value analysis. A total of 604 sites were sig-
nificant in Models 1, 2, and 3 in the M-value analysis, 479 of
which overlap with the 511 significant sites in Models 1, 2, and 3
of the b-value analysis. All 12 pyrosequenced sites were among
the 604 overlapping sites.
Because our cohorts included subjects with and without
COPD, we performed a sensitivity analysis examining differen-
tial methylation in subjects with obstructive lung disease (nICGN¼
643; nEOCOPD ¼ 223). The characteristics of this subgroup are
illustrated in Table E6. The difference in mean FEV1 % pre-
dicted by current systemic steroid use was attenuated, whereas
the difference in pack-years between the groups is no longer
significant. Using the same criteria for significance as used in
our primary analyses, 484 CpG sites demonstrated significant
differential methylation with respect to current systemic steroid
use in Model 1; the top 20 most highly associated sites are re-
ported in Table 5, and the full list is reported in Table E7. A total
of 461 of these sites overlap with the 614 sites identified in the
corresponding analysis in the full cohort. For Model 2, 468 CpG
sites were differentially methylated in the COPD-only analysis;
448 of these sites overlap with the 599 sites identified using the
full cohort (Table E8). For Model 3, 397 CpG sites were differ-
entially methylated; 384 of these overlap with the 524 sites from
the full cohort analysis (Table E9). A total of 392 CpG sites were
significant in all three models in the COPD-only analyses; 371 of
these sites overlap with the 511 CpG sites identified in the full-
cohort analyses (Table E10).
Acute exacerbations, which are the most common indication
for systemic steroid use in our study populations, are known to
increase as lung function declines (29) and to decrease with
inhaled corticosteroid use (30). We examined the impact of
these two important confounders in separate exploratory anal-
yses. First, we performed an epigenome-wide association anal-
ysis using Model 1 and replaced current systemic steroid use
with inhaled corticosteroid use as the independent predictor;
no significantly differentially methylated sites were found. Sec-
ond, although our primary analyses adjusted for differences in
lung function by including FEV1 % predicted as a covariate, we
sought to further mitigate the differences in disease severity by
performing a matched analysis in a subgroup of subjects in
TABLE 2. TOP 20 CPG SITES WITH SIGNIFICANT DIFFERENTIAL METHYLATION BY CURRENT SYSTEMIC STEROID USE (MODEL 1)
CpG names Gene Symbol
ICGN EOCOPD
Liptak Combined P ValueDifference in Mean Methylation* P Value† Difference in Mean Methylation* P Value‡
cg19906550 SLC22A18 20.10 5.96 3 10235 20.05 3.56 3 1024 4.71 3 10237
cg27461196 FXYD1 20.15 1.80 3 10233 20.08 3.40 3 1024 1.27 3 10235
cg25600606 HIPK3 20.15 9.29 3 10234 20.08 7.95 3 1024 1.76 3 10235
cg08700306 LRP3 20.09 3.60 3 10233 20.05 2.85 3 1024 2.07 3 10235
cg09868035 ABHD16B 20.09 7.93 3 10233 20.05 1.47 3 1023 2.97 3 10234
cg17709873 LTA 0.10 3.36 3 10232 0.06 7.32 3 1024 5.32 3 10234
cg01526089 P2RX1 20.13 5.38 3 10233 20.06 3.52 3 1023 6.29 3 10234
cg00795812 PDCD1 0.09 7.21 3 10233 0.05 4.05 3 1023 1.01 3 10233
cg18884741 RABGEF1 20.17 1.98 3 10232 20.07 7.69 3 1023 6.61 3 10233
cg07730301 ALDH3B1 20.10 3.29 3 10231 20.05 1.06 3 1023 7.58 3 10233
cg26215727 SCNN1A 20.09 2.33 3 10229 20.05 4.82 3 1025 2.13 3 10232
cg21019522 SLC22A18 20.08 2.50 3 10229 20.04 5.59 3 1024 2.60 3 10231
cg06270401 DYRK4 20.12 1.10 3 10229 20.06 2.69 3 1023 7.14 3 10231
cg25634666 FOLR3 20.11 6.60 3 10229 20.06 8.15 3 1024 1.02 3 10230
cg00974864 FCGR3B 20.11 2.50 3 10228 20.06 5.92 3 1024 2.68 3 10230
cg08368934 GPR97 20.10 5.13 3 10229 20.06 2.36 3 1023 2.71 3 10230
cg17823175 AZU1 20.12 1.41 3 10227 20.07 1.62 3 1024 4.00 3 10230
cg00645579 IRF7 20.09 2.08 3 10227 20.05 6.08 3 1024 2.23 3 10229
cg15518883 SIT1 0.08 4.44 3 10227 0.05 3.03 3 1024 2.32 3 10229
cg24211388 AIF1 20.12 3.02 3 10228 20.06 5.40 3 1023 4.29 3 10229
Definition of abbreviations: EOCOPD ¼ Early Onset COPD Study; ICGN ¼ International COPD Genetics Network.
*Difference in mean methylation ¼ (mean methylation subjects on steroids) 2 (mean methylation subjects not on steroids). Methylation values may range from 0 to 1.
y P value from regression Model 1 (adjusted for age, sex, and FEV1 % predicted)
zOne-sided P value from regression Model 1.
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ICGN matched on age, gender, and FEV1 % predicted. We
examined the differences in mean methylation at the 511 over-
lapping significant CpG sites from our primary analyses; all 511
sites continued to demonstrate a significant (P , 0.05) differ-
ence in mean methylation by current systemic steroid use, with
a consistent direction of effect as that observed in the full cohort
analysis (Table E11).
DISCUSSION
The most well studied epigenetic processes investigating sys-
temic steroid exposure are histone modifications, and consider-
able evidence supports a link between histone acetylation and
steroid resistance (2, 12). Investigations into the role of DNA
methylation have been limited to the study of various candidate
genes, such as the cytochrome P450 enzymes (31–35), trans-
porter proteins (36–38), or the glucocorticoid receptor (4, 39)
itself. Given the broad effects of systemic steroids, including
evidence supporting a dose-dependent effect on DNA methyl-
transferase expression (7), we hypothesized that exposure to
systemic steroids may be associated with differential methyla-
tion at multiple loci throughout the genome. We now report the
first genome-wide analysis of the association between glucocor-
ticoids and DNA methylation in peripheral blood. Our analyses
suggest differential methylation at numerous, specific CpG
dinucleotides throughout the genome located in established as
well as previously unsuspected pathways.
Because systemic corticosteroids are often administered for
their antiinflammatory and immune-modulating properties, sig-
nificant associations with CpG sites annotated to genes located
within these pathways can be viewed as biologically plausible.
Examples include members of the tumor necrosis factor super-
family, such as lymphotoxin a (LTA), tumor necrosis factor
ligands (TNFSF12, TNFSF13B, and TNFSF12-TNFSF13),IL-1b
and IL-2, and various receptors such as CD27, Fc fragment of
IgG, low-affinity IIIb receptor (FCGR3B), and chemokine re-
ceptor 2 (CXCR2). Several of the CpG sites validated through
pyrosequencing are also involved in immune responses. Azurocidin
1 (AZU1), also known as heparin binding protein, is a peptide
with antimicrobial, chemotactic, and inflammatory mediator
properties contained within the azurophilic granules of neutro-
phils (40–42). The signaling threshold regulating transmembrane
adaptor 1 (SIT1) has been shown to have a role in T-cell recep-
tor–mediated signaling (43, 44). Interferon regulatory factor 7
(IRF7) is involved in mediating the expression of interferon a
and the response to viral infection (45, 46); interestingly, rela-
tive hypermethylation at the IRF7 promoter has been corre-
lated with decreased expression in the nasal epithelium of
smokers (47).
CpG sites annotated to processes associated with well ac-
cepted, clinically relevant side effects of therapeutic glucocorti-
coids, such as hyperglycemia/insulin resistance, weight gain, and
osteoporosis, can also be viewed as biologically plausible associ-
ations. Examples of genes implicated in such processes include
the insulin receptor (INSR), leptin (LEP), and the cytochrome
P450, family 27, subfamily B, polypeptide 1 (CYP27B1), a pro-
tein better known as 25-OH vitamin D-1a-hydroxylase, which is
involved in calcium homeostasis through the conversion of vi-
tamin D into its active form (48). Associations with genes in-
volved in the synthesis and regulation of steroid hormones also
appear logical. An example is cg25600606, a highly associated
and validated site, located within the homeodomain-interacting
protein kinase 3 (HIPK3) gene, a serine–threonine protein ki-
nase that participates in cAMP-mediated steroidogenesis (49).
Although associations with genes annotated to biologically
plausible pathways can be viewed as proof-of-concept associa-
tions, the greater value of a genome-wide approach may lie in
exploring genes and pathways that do not have an obvious biolog-
ical relevance. Three strongly associated and validated examples
include the abhydrolase domain containing 16B (ABHD16B), the
lipoprotein receptor–related protein (LRP3), and G protein–
coupled receptor 97 (GPR97). Very little is known about the
structure and function of ABHD16B. GPR97 was discovered
through a search of human genome databases and, based on
the general function of G protein–coupled receptors, may be
involved in signal transduction (50). LRP3 displays significant
structural homology to the low-density lipoprotein receptors;
however, functional studies demonstrated no significant binding
of LRP3 to receptor-associated protein (RAP). Thus, the bio-
logical function of LRP3 may be distinct from lipoprotein me-
tabolism (51).
Cg19906550 and cg21019522 map to the solute carrier family 22,
member 18 (SLC22A18) gene. This gene encodes a poly-specific
TABLE 3. SIGNIFICANTLY ENRICHED TERMS FROM FUNCTIONAL
ANNOTATION CLUSTERING* PERFORMED ON GENES





GO:0031224 Intrinsic to membrane 2.5 3 1022
GO:0007599 Hemostasis 8.7 3 1024
GO:0050878 Regulation of body fluid
levels
2.6 3 1023
GO:0050817 Coagulation 4.1 3 1023
GO:0007596 Blood coagulation 4.1 3 1023
GO:0048878 Chemical hemostasis 2.2 3 1023




GO:0050801 Ion homeostasis 4.0 3 1022
GO:0042592 Homeostatic process 2.8 3 1022









GO:0030595 Leukocyte chemotaxis 7.5 3 1023
GO:0060326 Cell chemotaxis 9.7 3 1023
GO:0050900 Leukocyte migration 1.4 3 1022
GO:0055074 Calcium ion homeostasis 7.7 3 1023
GO:0055066 Di-, trivalent inorganic
cation homeostasis
1.1 3 1022
GO:0006874 Cellular calcium ion
homeostasis
1.4 3 1024
GO:0055065 Metal ion homeostasis 1.5 3 1022




GO:0007204 Elevation of cytosolic calcium
ion concentration
1.7 3 1022
GO:0006875 Cellular metal ion homeostasis 2.6 3 1022
GO:0051480 Cytosolic calcium ion
homeostasis
2.8 3 1022
GO:0030003 Cellular cation homeostasis 3.9 3 1022
GO:0051222 Positive regulation of
protein transport
9.6 3 1023
GO:0042330 Taxis 3.1 3 1022
GO:0006935 Chemotaxis 3.1 3 1022
GO:0002683 Negative regulation of
immune system process
3.0 3 1022
GO:0051250 Negative regulation of
lymphocyte activation
4.0 3 1022
GO:000758 Response to nutrient 3.0 3 1022
* Functional annotation clustering performed using the Database for Annotation,
Visualization, and Integrated Discovery (DAVID) Bioinformatics Resources 6.7.
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cation transporter and lies within the 11p15.5 region known to
contain multiple well characterized imprinted genes such as
insulin-like growth factor 2 (IGF2) andH19 (52, 53). SLC22A18
appears to be subject to imprinting as well, though the strength
of the resulting allelic expression bias appears to vary by tissue
(52, 53), developmental stage (53), and individual (52–54). The
degree to which DNA methylation contributes to differences in
allelic expression is unclear (55); although increased methyla-
tion at the SLC22A18 promoter has been described in the con-
text of several different tumors, the correlation with expression
changes remains imperfect and varies by tissue and tumor type
(55–57).
Another validated site, cg26215727, is located within the so-
dium channel, non–voltage-gated 1 a subunit (SCNN1A) gene.
This gene encodes the a subunit of an amiloride-sensitive epithelial
sodium channel that is critical in regulating fluid transport in var-
ious organs such as the lung, kidney, liver, and pancreas (58, 59).
The promoter of the SCNN1A gene is known to contain a gluco-
corticoid response element (GRE) (60), and several studies have
demonstrated increased expression of SCNN1A associated with
increased endogenous (61) or exogenously administered (60, 62)
glucocorticoids.
We therefore explored whether additional putative GREs
were in close proximity to the differentially methylated sites
identified in our analyses. Because GREs are defined through
a combination of relatively short (15 base pair), often variable
consensus sequences and, more importantly, functional valida-
tion by demonstrating direct glucocorticoid receptor (GR) bind-
ing or reduced inducibility after deletion or mutation of the
putative GRE, exhaustive studies examining putative GREs
on a genome-wide scale have been limited. In a study by Reddy
and colleagues (63), chromatin immunoprecipitation followed by
sequencing (CHiP-seq) was used to assess GR binding through-
out the genome in A549 human lung epithelial carcinoma cell
TABLE 4. PYROSEQUENCING VALIDATION OF SELECTED CpG SITES IN THE INTERNATIONAL
CHRONIC OBSTRUCTIVE PULMONARY DISEASE GENETICS NETWORK COHORT
CpG Gene Symbol Completion Rate Difference in Mean Methylation* P Value†
cg19906550 SLC22A18 97.4% 20.08 5.78 3 10213
cg21019522 SLC22A18 97.3% 20.06 2.14 3 10211
cg08700306 LRP3 97.5% 20.11 2.78 3 10212
cg25600606 HIPK3 94.2% 20.15 6.29 3 10214
cg26215727 SCNN1A 96.8% 20.12 2.20 3 10216
cg27461196 FXYD1 96.8% 20.13 2.33 3 1026
cg00645579 IRF7 98.0% 20.10 2.20 3 10216
cg17823175 AZU1 95.6% 20.07 5.11 3 1028
cg15518883 SIT1 97.9% 0.08 1.77 3 10212
cg08368934 GPR97 97.1% 20.09 3.73 3 10212
cg09868035 ABHD16B 98.2% 20.07 1.45 3 1028
cg18884741 RABGEF1 85.3% 20.09 4.94 3 1026
*Difference in mean methylation ¼ (mean methylation in subjects on current steroids) – (mean methylation in subjects
NOT on steroids). Methylation values range from 0 to 1.
y P value for unpaired Student’s t test.
TABLE 5. TOP 20 CpG SITES WITH DIFFERENTIAL METHYLATION BY CURRENT SYSTEMIC STEROID USE IN SUBJECTS WITH OBSTRUCTIVE











cg25600606 HIPK3 20.15 5.93 3 10227 20.07 2.90 3 1023 4.47 3 10228 Yes
cg19906550 SLC22A18 20.10 3.15 3 10226 20.05 1.79 3 1023 1.24 3 10227 Yes
cg27461196 FXYD1 20.15 3.45 3 10226 20.07 1.92 3 1023 1.48 3 10227 Yes
cg08700306 LRP3 20.09 1.16 3 10225 20.05 1.60 3 1023 3.86 3 10227 Yes
cg18884741 RABGEF1 20.16 1.90 3 10226 20.06 2.46 3 1022 2.99 3 10226 Yes
cg17709873 LTA 0.10 3.03 3 10225 0.06 4.43 3 1023 3.41 3 10226 Yes
cg09868035 ABHD16B 20.09 3.19 3 10225 20.04 6.52 3 1023 5.96 3 10226 Yes
cg01526089 P2RX1 20.13 2.71 3 10225 20.05 8.29 3 1023 7.08 3 10226 Yes
cg07730301 ALDH3B1 20.09 5.47 3 10225 20.04 5.41 3 1023 7.82 3 10226 Yes
cg26215727 SCNN1A 20.09 4.52 3 10223 20.05 1.09 3 1024 8.78 3 10226 Yes
cg00795812 PDCD1 0.09 2.11 3 10225 0.04 1.30 3 1022 1.06 3 10225 Yes
cg17823175 AZU1 20.12 2.63 3 10223 20.06 1.28 3 1023 6.02 3 10225 Yes
cg25634666 FOLR3 20.10 1.14 3 10223 20.05 4.40 3 1023 1.13 3 10224 Yes
cg06270401 DYRK4 20.12 5.48 3 10224 20.05 1.05 3 1022 1.75 3 10224 Yes
cg00974864 FCGR3B 20.11 3.60 3 10223 20.05 2.87 3 1023 2.03 3 10224 Yes
cg21019522 SLC22A18 20.08 9.62 3 10223 20.04 3.12 3 1023 5.84 3 10224 Yes
cg08368934 GPR97 20.10 2.30 3 10223 20.04 1.10 3 1022 7.35 3 10224 Yes
cg24211388 AIF1 20.12 2.48 3 10223 20.05 1.14 3 1022 8.30 3 10224 Yes
cg10758292 DEFA1 20.13 2.66 3 10222 20.06 2.85 3 1023 1.41 3 10223 Yes
cg05681757 FGD4 20.09 6.46 3 10221 20.05 2.30 3 1024 2.51 3 10223 Yes
Definition of abbreviations: EOCOPD ¼ Early Onset COPD Study; ICGN ¼ International COPD Genetics Network.
*Difference in mean methylation ¼ (mean methylation subjects on steroids) 2 (mean methylation subjects not on steroids). Methylation values range from 0 to 1.
y P value from regression Model 1 (adjusted for age, sex, and FEV1 % predicted).
zOne-sided P value from regression model.
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lines 1 hour after exposure to dexamethasone. The median dis-
tance of GR binding to the transcription start site of a gene was
11 kb for up-regulated genes and 146 kb for down-regulated
genes. We therefore examined whether any GR binding sites
(as described by Reddy and colleagues [63]) were located
within 611 kb and 6146 kb of the 511 CpG sites significant in
all three models of our primary analysis. Thirty-nine sites had at
least one putative GR binding site within 11 kb, whereas 230
CpG sites had at least one GR binding site within 146 kb (Table
E12).
Extensive differential gene expression in blood after the ad-
ministration of exogenous glucocorticoids has been described in
vivo and in vitro. In additional exploratory analyses, we exam-
ined the overlap between genes with differential methylation
from our study (475 unique genes from the 511 overlapping
significant sites from our primary analysis) and loci with differ-
ential expression reported in the literature. Menke and col-
leagues (8) examined differential gene expression in blood 3
hours after a single dose of dexamethasone in healthy control
subjects and in subjects with depression. Of 2,760 differentially
expressed transcripts reported in their healthy control subjects,
97 transcripts (in 78 unique genes) overlapped with differen-
tially methylated loci from our study (Table E13); 76 of these
transcripts (in 60 unique genes), including transcripts for
SLC22A18, HIPK3, and LRP3, demonstrated an anticorre-
lated direction of effect relative to the methylation changes
in our cohort. In depressed subjects, 1,151 transcripts were
differentially expressed in Menke and colleagues (8). Forty
transcripts (in 36 unique genes) overlapped with our loci
(Table E14); 29 of these transcripts (in 25 unique genes) dem-
onstrated an anticorrelated direction of effect. In contrast to
the acute exposure studied by Menke and colleagues (8), Lit
and colleagues examined differential expression in children
and adolescents with Duchenne’s muscular dystrophy exposed
to chronic glucocorticoids (64). Of the 524 differentially ex-
pressed probes reported, 40 transcripts (in 31 unique genes) were
annotated to genes that overlap with our differentially methyl-
ated sites (Table E15); 36 of the transcripts (in 28 unique genes)
demonstrated an anticorrelated direction of effect relative to the
changes in methylation in our cohort. Finally, we examined pub-
licly available gene expression data (Gene Expression Omnibus
accession number GSE29342) obtained in lymphocyte cell lines
exposed to dexamethasone for 1 hour, as reported by Maranville
and colleagues (9). A total of 467 transcripts (in 327 unique
genes) were annotated to genes identified as containing a dif-
ferentially methylated CpG site from our analyses. Of these,
206 transcripts (in 155 unique genes) demonstrated nominal
differential methylation (unadjusted Student’s t test, P ,
0.05). The results are summarized in Table E16. Additional
studies in populations with contemporaneous functional or
experimental data are needed.
Although our study used two large, independent cohorts and
rigorous statistical thresholds for significance, we acknowledge
the following limitations that may affect the interpretation or
generalizability of the results reported herein. First, we rely upon
subjects’ self-report to define current steroid use and do not
have details regarding the dosage, timing, or duration of expo-
sure to therapeutic steroids. Second, we do not know the degree
to which cell type heterogeneity affects our results. Third, al-
though we assessed the methylation at over 26,000 autosomal
sites in our analysis, coverage of the genome is relatively sparse,
with an average of only two CpG sites per gene. Genes that
have previously been implicated in the response to steroids,
such as the glucocorticoid-induced transcript 1 (GLCCI1)
(65), were not assayed on our platform. An additional concern
regarding the use of an array-based platform is the unknown
impact of sequence and structural variations on these platforms;
this is an area of active controversy in the field and underscores
the importance of technical validation through a second tech-
nology. Although it was not feasible for us to evaluate all of the
statistically significant sites through pyrosequencing, all of the
sites we pyrosequenced remained robustly associated with dif-
ferences in mean methylation comparable to the estimates ob-
tained through the array-based data. Finally, we acknowledge
difficulty in delineating the degree to which the reported asso-
ciations are confounded by the indication for steroid use (i.e., to
what degree the reported epigenetic changes are associated with
decreased lung function or COPD exacerbations rather than
with systemic steroid use). Several highly associated sites from
our analysis, including FXYD1 and LRP3, were previously re-
ported to be associated with FEV1 % predicted and with the
FEV1/FVC ratio (66). LRP3 was noted to be differentially
expressed after systemic glucocorticoid exposure among the
healthy control subjects studied by Menke and colleagues (8).
Additional studies of DNA methylation in populations with
longitudinal data and in populations not ascertained on lung
disease are needed. Despite these limitations, we contend that
our analyses support the hypothesis that systemic steroid use is
associated with site-specific differential methylation throughout
the genome. The CpG sites identified in our study are located in
biologically plausible and previously unsuspected pathways,
some of which may be relevant to the development of novel
targeted therapies in the future.
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